Cure, Therapix to develop cannabinoid-based treatment for sleep disorders

Cure Pharmaceutical recently announced a product development agreement with Therapix Bisociences for cannabinoid-based treatments.

The partnership will focus on a proprietary cannabinoid-based product on Cure’s CureFilm, a multilayer oral thin film, for the treatment of sleep disorders.

“We are enthusiastic about this next phase in our strategic partnership with Therapix. This product development agreement serves as testament that we are delivering on the goal we set forth when we first partnered in July to pool our expertise and resources to develop new products,” Rob Davidson, MPH, CEO of Cure, said in a press release. “Our main goal at Cure is to improve people’s lives by redefining how medications are delivered, and sleep disorders is a medical indication with high unmet need that I think we can significantly impact.”

The agreement is an extension of a recently announced partnership between Cure, Therapix and Assuta Medical Centers to develop novel therapeutic products in personalized medicine and cannabinoids.

Cure will develop a combination of 2.5 mg of dronabinol and 200 mg of palmitoylethanolamide on its oral thin film technology.

A feasibility study has been completed for the new product and Cure will begin proof of concept in the near future, according to the release.

Cure Pharmaceutical recently announced a product development agreement with Therapix Bisociences for cannabinoid-based treatments.

The partnership will focus on a proprietary cannabinoid-based product on Cure’s CureFilm, a multilayer oral thin film, for the treatment of sleep disorders.

“We are enthusiastic about this next phase in our strategic partnership with Therapix. This product development agreement serves as testament that we are delivering on the goal we set forth when we first partnered in July to pool our expertise and resources to develop new products,” Rob Davidson, MPH, CEO of Cure, said in a press release. “Our main goal at Cure is to improve people’s lives by redefining how medications are delivered, and sleep disorders is a medical indication with high unmet need that I think we can significantly impact.”

The agreement is an extension of a recently announced partnership between Cure, Therapix and Assuta Medical Centers to develop novel therapeutic products in personalized medicine and cannabinoids.

Cure will develop a combination of 2.5 mg of dronabinol and 200 mg of palmitoylethanolamide on its oral thin film technology.

A feasibility study has been completed for the new product and Cure will begin proof of concept in the near future, according to the release.